A. Associated urinary tract infections (correct)

B. Associated urinary tract infections (incorrect)

C. Multiple sclerosis (incorrect)

D. Cauda equina syndrome (incorrect)

E. DDAVP (incorrect)

F. DDAVP (incorrect)

G. DDAVP (incorrect)

H. DDAVP (incorrect)

I. DDAVP (incorrect)

J. DDAVP (incorrect)

K. DDAVP (incorrect)

L. DDAVP (incorrect)

M. DDAVP (incorrect)

N. DDAVP (incorrect)

O. DDAVP (incorrect)

P. DDAVP (incorrect)

Q. DDAVP (incorrect)

R. DDAVP (incorrect)

S. DDAVP (incorrect)

T. DDAVP (incorrect)

U. DDAVP (incorrect)

V. DDAVP (incorrect)

W. DDAVP (incorrect)

X. DDAVP (incorrect)

Y. DDAVP (incorrect)

Z. DDAVP (incorrect)

A. Associated urinary tract infections (correct)

B. Associated urinary tract infections (incorrect)

C. Multiple sclerosis (incorrect)

D. Cauda equina syndrome (incorrect)

E. DDAVP (incorrect)

F. DDAVP (incorrect)

G. DDAVP (incorrect)

H. DDAVP (incorrect)

I. DDAVP (incorrect)

J. DDAVP (incorrect)

K. DDAVP (incorrect)

L. DDAVP (incorrect)

M. DDAVP (incorrect)

H. DDAVP (incorrect)

J. DDAVP (incorrect)

K. DDAVP (incorrect)

L. DDAVP (incorrect)

M. DDAVP (incorrect)

N. DDAVP (incorrect)

O. DDAVP (incorrect)

P. DDAVP (incorrect)

Q. DDAVP (incorrect)

R. DDAVP (incorrect)

S. DDAVP (incorrect)

T. DDAVP (incorrect)

U. DDAVP (incorrect)

V. DDAVP (incorrect)

W. DDAVP (incorrect)

X. DDAVP (incorrect)

Y. DDAVP (incorrect)

Z. DDAVP (incorrect)

For a neurogenic bladder dysfunction, such as an idiopathic detrusor overactivity, a lack of arginine vasopressin (DDAVP) release/insensitivity or a DDAVP resistance may prove efficacious in reducing or curing the voiding dysfunction.

1. A. Arm and leg restraints (correct)

2. B. Bed alarm (correct)

3. C. Desmopressin (correct)

4. D. Promontory (incorrect)

5. E. Prompted voiding (correct)

6. F. Combined toileting and exercise therapy (correct)

7. G. Combined toileting and exercise therapy (incorrect)

8. H. Combined toileting and exercise therapy (incorrect)

9. I. Combined toileting and exercise therapy (incorrect)

10. J. Combined toileting and exercise therapy (incorrect)

11. K. Combined toileting and exercise therapy (incorrect)

12. L. Combined toileting and exercise therapy (incorrect)

13. M. Combined toileting and exercise therapy (incorrect)

14. N. Combined toileting and exercise therapy (incorrect)

15. O. Combined toileting and exercise therapy (incorrect)

16. P. Combined toileting and exercise therapy (incorrect)

17. Q. Combined toileting and exercise therapy (incorrect)

18. R. Combined toileting and exercise therapy (incorrect)

19. S. Combined toileting and exercise therapy (incorrect)

20. T. Combined toileting and exercise therapy (incorrect)

21. U. Combined toileting and exercise therapy (incorrect)

22. V. Combined toileting and exercise therapy (incorrect)

23. W. Combined toileting and exercise therapy (incorrect)

24. X. Combined toileting and exercise therapy (incorrect)

25. Y. Combined toileting and exercise therapy (incorrect)

26. Z. Combined toileting and exercise therapy (incorrect)

For a neurogenic bladder dysfunction, such as an idiopathic detrusor overactivity, a lack of arginine vasopressin (DDAVP) release/insensitivity or a DDAVP resistance may prove efficacious in reducing or curing the voiding dysfunction.

For a neurogenic bladder dysfunction, such as an idiopathic detrusor overactivity, a lack of arginine vasopressin (DDAVP) release/insensitivity or a DDAVP resistance may prove efficacious in reducing or curing the voiding dysfunction.

For a neurogenic bladder dysfunction, such as an idiopathic detrusor overactivity, a lack of arginine vasopressin (DDAVP) release/insensitivity or a DDAVP resistance may prove efficacious in reducing or curing the voiding dysfunction.
ACTIVITY TITLE: OAB in Special Populations
DATES VALID: 2011
CREDITS AVAILABLE: 1 Category 2B, AOA; 1 Category 1 AMA PRA™

INSTRUCTIONS: Please complete this form and return it to the address or fax number below.

PLEASE PRINT CLEARLY

FULL NAME: 

Last 4 digits of SSN: (for tracking)

MAILING ADDRESS: 

PHONE: 

FAX: 

E-MAIL: 

<table>
<thead>
<tr>
<th>QUESTION RESPONSES</th>
<th>PROGRAM EVALUATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q#</td>
<td>A</td>
</tr>
<tr>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

LEARNING OBJECTIVES

1. To understand the risk factors for children with overactive bladder, and the evaluation and treatment of simple nocturnal enuresis in children.

2. To understand the specialized evaluation and treatment of overactive bladder in the elderly.

3. To be able to distinguish neurogenic versus non-neurogenic causes of overactive bladder symptoms.

CONTENT

4. To what extent this activity is fair and balanced.

5. Likelihood that you will implement change in your practice based on information from this activity.

6. Your OVERALL rating of this activity.

PRACTICE

7. How will you use the information presented to improve the care of your patients?